Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Roche closes $46.8 billion Genentech deal
Zurich, Switzerland - Roche Holding AG has sealed a deal with Genentech to buy the 44 percent of the company that it doesn't already own for $95 a share, CNNMoney.com reports.
Zurich, Switzerland
- Roche Holding AG has sealed a deal with Genentech to buy the 44 percent of the company that it doesn't already own for $95 a share, CNNMoney.com reports.
This agreement ends an eight-month battle, in which Genentech repeatedly rejected Roche’s offer. The price was negotiated from $93 per share to $95, which a Genentech board member says is a fair offer to shareholders, according to CNNMoney.com.
Recent Videos
Related Content
